Press Releases

Promedior to Present Corporate Overview at Wedbush Securities Life Sciences Management Access Conference

LEXINGTON, Mass., August 5, 2014 — Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that Suzanne L. Bruhn, Ph.D., President and Chief Executive Officer, will present at the Wedbush Securities Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:20 a.m. EDT at Le Parker Meridien Hotel in New York, NY.

About Promedior
Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat rare diseases involving fibrosis. Its proprietary development platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, preventing and potentially reversing fibrosis. PRM-151, the Company’s lead candidate, is in a Phase 2 trial for myelofibrosis, and preliminary data demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. PRM-151 has also been tested in idiopathic pulmonary fibrosis, or IPF, and data from a Phase 1b study of PRM-151 in IPF patients resulted in a mean improvement in Forced Vital Capacity at 8 weeks. PRM-151 was well tolerated in both studies. For more information about Promedior, please visit www.promedior.com.

Investor Contact:
Lilian Stern
Stern Investor Relations
+1-212-362-1200
lilian@sternir.com

PTX-2

Crystal structure of human Pentraxin-2, a naturally occurring protein that is the foundation of Promedior's proprietary platform. Learn More >